Ursal, Kent B.
HRN: 22-41-36 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/08/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/08/2023
01/14/2023
IVT
35mg
OD
Neonatal Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes